Immune checkpoint signaling and cancer immunotherapy

PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation

(2020) Kenji Shimizu et al.   MOLECULAR CELL

Molecular mechanism of SHP2 activation by PD-1 stimulation

(2020) M. Marasco et al.   Science Advances

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

(2019) Han Yao et al.   Nature Biomedical Engineering

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

(2019) Daisuke Sugiura et al.   SCIENCE

Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks

(2019) Andreia Peixoto et al.   Frontiers in Oncology

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy

(2019) Yan Zhang et al.   CELL RESEARCH

The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis

(2019) Michelle A. Mintz et al.   IMMUNITY

TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma

(2019) Xiaochen Wang et al.   JOURNAL OF HEPATOLOGY

Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy

(2019) Javier Celis-Gutierrez et al.   Cell Reports

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

(2019) Yunlong Zhao et al.   IMMUNITY

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion

(2018) Lyndsay Avery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells

(2018) Yunlong Zhao et al.   Cell Reports

Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo

(2018) Giorgia Rota et al.   Cell Reports

PD-L1 binds to B7-1 only in cis on the same cell surface

(2018) Apoorvi Chaudhri et al.   Cancer Immunology Research

LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis

(2018) David Bauché et al.   IMMUNITY

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells

(2018) Xiangbo Meng et al.   NATURE

HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity

(2018) Huanbin Wang et al.   Nature Chemical Biology

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

(2018) Takumi Maruhashi et al.   NATURE IMMUNOLOGY

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor

(2017) Michael Peled et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells

(2017) Masahiro Okada et al.   Cell Reports

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Glycosylation-directed quality control of protein folding

(2015) Chengchao Xu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy

(2015) B. Lo et al.   SCIENCE

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

(2014) F. Xu et al.   CANCER RESEARCH

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

(2014) Man Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II

(2014) Bitao Liang et al.   JOURNAL OF IMMUNOLOGY

Rab8 Binding to Immune Cell-Specific Adaptor LAX Facilitates Formation of trans-Golgi Network-Proximal CTLA-4 Vesicles for Surface Expression

(2014) M. C. Banton et al.   MOLECULAR AND CELLULAR BIOLOGY

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

Protein kinase C-η controls CTLA-4–mediated regulatory T cell function

(2014) Kok-Fai Kong et al.   NATURE IMMUNOLOGY

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

(2013) Noa Stanietsky et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

T Cell Ig and Mucin Domain-Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases

(2013) K. L. Clayton et al.   JOURNAL OF IMMUNOLOGY

p58IPK-Mediated Attenuation of the Proapoptotic PERK-CHOP Pathway Allows Malignant Progression upon Low Glucose

(2013) Anne-Laure Huber et al.   MOLECULAR CELL

Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma

(2013) F. Guillaumond et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

(2012) S Liu et al.   CELL DEATH AND DIFFERENTIATION

Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation

(2012) Omar S. Qureshi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion

(2012) Manu Rangachari et al.   NATURE MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

(2011) Steven D. Levin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

(2011) N. Joller et al.   JOURNAL OF IMMUNOLOGY

Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways

(2011) J. Lee et al.   MOLECULAR AND CELLULAR BIOLOGY

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis

(2011) Haik Mkhikian et al.   Nature Communications

Spatiotemporal Basis of CTLA-4 Costimulatory Molecule-Mediated Negative Regulation of T Cell Activation

(2010) Tadashi Yokosuka et al.   IMMUNITY

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

(2010) Rosemarie H. DeKruyff et al.   JOURNAL OF IMMUNOLOGY

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

(2009) M. Nakayama et al.   BLOOD

T Cell Intrinsic Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding Microenvironment

(2009) T. C. Cheung et al.   JOURNAL OF IMMUNOLOGY

Pathways and mechanisms of endocytic recycling

(2009) Barth D. Grant et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Unconventional ligand activation of herpesvirus entry mediator signals cell survival

(2009) T. C. Cheung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

(2009) N. Stanietsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator

(2008) Guifang Cai et al.   NATURE IMMUNOLOGY

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY

Coordinated protein sorting, targeting and distribution in polarized cells

(2008) Ira Mellman et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE